

## **MALATTIE INFETTIVE**

Studio Osservazionale **MV22255 "GUARD-C"**-Global observational cohort study on the prediction of unwanted adverse effects in individuals infected with chronic hepatitis C receiving a long-acting interferon plus ribavirin-

Sperimentatore Dott. Filippo Matarazzo